34 results on '"Mariampillai, Kuberaka"'
Search Results
2. CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis
- Author
-
Dzangué-Tchoupou, Gaëlle, Mariampillai, Kuberaka, Bolko, Loïs, Amelin, Damien, Mauhin, Wladimir, Corneau, Aurélien, Blanc, Catherine, Allenbach, Yves, and Benveniste, Olivier
- Published
- 2019
- Full Text
- View/download PDF
3. Inclusion-body myositis associated with Sjögren’s disease: clinical characteristics and comparison with other Sjögren-associated myositis
- Author
-
Astouati, Quentin, primary, Machet, Thomas, additional, Houssais, Camille, additional, Noury, Jean-Baptiste, additional, Allenbach, Yves, additional, Gallay, Laure, additional, Quere, Baptiste, additional, Assan, Florence, additional, Benveniste, Olivier, additional, Broner, Jonathan, additional, Duffau, Pierre, additional, Espitia, Alexandra, additional, Grasland, Anne, additional, Hayem, Gilles, additional, Guern, Véronique Le, additional, Martis, Nihal, additional, Mariampillai, Kuberaka, additional, Nocturne, Gaëtane, additional, Mariette, Xavier, additional, Meyer, Alain, additional, Mulleman, Denis, additional, Devauchelle-Pensec, Valérie, additional, Collet, Aurore, additional, Launay, David, additional, Hachulla, Eric, additional, Cornec, Divi, additional, Guellec, Dewi, additional, and Sanges, Sébastien, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis
- Author
-
Dieudonné, Yannick, Allenbach, Yves, Benveniste, Olivier, Leonard-Louis, Sarah, Hervier, Baptiste, Mariampillai, Kuberaka, Nespola, Benoit, Lannes, Béatrice, Echaniz-Laguna, Andoni, Wendling, Daniel, Von Frenckell, Christian, Poursac, Nicolas, Mortier, Emmanuel, Lavigne, Christian, Hinschberger, Olivier, Magnant, Julie, Gottenberg, Jacques-Eric, Geny, Bernard, Sibilia, Jean, and Meyer, Alain
- Published
- 2019
- Full Text
- View/download PDF
5. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study
- Author
-
Pijnenburg, Luc, primary, Giannini, Margherita, additional, Bouchard-Marmen, Maude, additional, Arnaud, Laurent, additional, Barsotti, Simone, additional, Bellando-Randone, Silvia, additional, Bernardi, Livio, additional, Bini, Paola, additional, Blagojevic, Jelena, additional, Codullo, Veronica, additional, Couderc, Marion, additional, De Moreuil, Claire, additional, Dernis, Emanuelle, additional, Diamanti, Luca, additional, Dubost, Jean Jacques, additional, Duval, Fanny, additional, Emmi, Giacomo, additional, Galempoix, Jean-Marc, additional, Geny, Bernard, additional, Gottenberg, Jacques-Eric, additional, Groza, Monica, additional, Guffroy, Aurelien, additional, Guichard, Isabelle, additional, Guilpain, Philippe, additional, Hervier, Baptiste, additional, Hudson, Marie, additional, Iaccarino, Luca, additional, Iannone, Florenzo, additional, Lebrun, Delphine, additional, Marchioni, Enrico, additional, Mariampillai, Kuberaka, additional, Maurier, Francois, additional, Mosca, Marta, additional, Nadaj-Pakleza, Aleksandra, additional, Nannini, Carlotta, additional, Piot, Jean-Maxime, additional, Prieto-González, Sergio, additional, Poursac, Nicolas, additional, Rouanet, Eglantine, additional, Sellam, Jérémie, additional, Selva-O'Callaghan, Albert, additional, Séverac, François, additional, Sibilia, Jean, additional, Sole, Guilhem, additional, Soulages, Antoine, additional, Terrier, Benjamin, additional, Tournadre, Anne, additional, Troyanov, Yves, additional, Vernier, Nathalie, additional, Vesperini, Veronique, additional, Viallard, Jean-François, additional, Ziane, Rahima, additional, Cavagna, Lorenzo, additional, and Meyer, Alain, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Innate and Adaptive Immune Response in Fabry Disease
- Author
-
Mauhin, Wladimir, Lidove, Olivier, Masat, Elisa, Mingozzi, Federico, Mariampillai, Kuberaka, Ziza, Jean-Marc, Benveniste, Olivier, Zschocke, Johannes, Editor-in-chief, Baumgartner, Matthias, editor, Morava, Eva, editor, Patterson, Marc, editor, Rahman, Shamima, editor, and Peters, Verena, editor
- Published
- 2015
- Full Text
- View/download PDF
7. Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis
- Author
-
Dieudonné, Yannick, Allenbach, Yves, Benveniste, Olivier, Leonard-Louis, Sarah, Hervier, Baptiste, Mariampillai, Kuberaka, Nespola, Benoit, Lannes, Béatrice, Echaniz-Laguna, Andoni, Wendling, Daniel, Von Frenckell, Christian, Poursac, Nicolas, Mortier, Emmanuel, Lavigne, Christian, Hinschberger, Olivier, Magnant, Julie, Gottenberg, Jacques-Eric, Geny, Bernard, Sibilia, Jean, and Meyer, Alain
- Published
- 2020
- Full Text
- View/download PDF
8. Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials
- Author
-
Hogrel, Jean-Yves, Allenbach, Yves, Canal, Aurélie, Leroux, Gaëlle, Ollivier, Gwenn, Mariampillai, Kuberaka, Servais, Laurent, Herson, Serge, Decostre, Valérie, and Benveniste, Olivier
- Published
- 2014
- Full Text
- View/download PDF
9. Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement
- Author
-
Allenbach, Yves, Arouche-Delaperche, Louiza, Preusse, Corinna, Radbruch, Helena, Butler-Browne, Gillian, Champtiaux, Nicolas, Mariampillai, Kuberaka, Rigolet, Aude, Hufnagl, Peter, Zerbe, Norman, Amelin, Damien, Maisonobe, Thierry, Louis-Leonard, Sarah, Duyckaerts, Charles, Eymard, Bruno, Goebel, Hans-Hilmar, Bergua, Cecile, Drouot, Laurent, Boyer, Olivier, Benveniste, Olivier, and Stenzel, Werner
- Published
- 2018
- Full Text
- View/download PDF
10. Anti-PM-Scl antibodies–positive patients encompass three different groups with distinct prognoses
- Author
-
Breillat, Paul, primary, Mariampillai, Kuberaka, additional, Legendre, Paul, additional, Martins, Pauline, additional, Dunogue, Bertrand, additional, Charuel, Jean Luc, additional, Miyara, Makoto, additional, Goulvestre, Claire, additional, Paule, Romain, additional, Vanquaethem, Helene, additional, Ackermann, Felix, additional, Benveniste, Olivier, additional, Nunes, Hilario, additional, Mouthon, Luc, additional, Allenbach, Yves, additional, and Uzunhan, Yurdagul, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature
- Author
-
Sanges, Sébastien, Yelnik, Cécile M., Sitbon, Olivier, Benveniste, Olivier, Mariampillai, Kuberaka, Phillips-Houlbracq, Mathilde, Pison, Christophe, Deligny, Christophe, Inamo, Jocelyn, Cottin, Vincent, Mouthon, Luc, Launay, David, Lambert, Marc, Hatron, Pierre-Yves, Rottat, Laurence, Humbert, Marc, and Hachulla, Eric
- Published
- 2016
- Full Text
- View/download PDF
12. Anti-PM-Scl antibodies–positive patients encompass three different groups with distinct prognoses.
- Author
-
Breillat, Paul, Mariampillai, Kuberaka, Legendre, Paul, Martins, Pauline, Dunogue, Bertrand, Charuel, Jean Luc, Miyara, Makoto, Goulvestre, Claire, Paule, Romain, Vanquaethem, Helene, Ackermann, Felix, Benveniste, Olivier, Nunes, Hilario, Mouthon, Luc, Allenbach, Yves, and Uzunhan, Yurdagul
- Subjects
- *
DISEASE relapse , *AUTOANTIBODIES , *HOSPITALS , *RESEARCH , *STATISTICS , *DECISION trees , *DISEASE progression , *PNEUMONIA , *SCIENTIFIC observation , *CONFIDENCE intervals , *ADRENOCORTICAL hormones , *SYSTEMIC scleroderma , *AUTOIMMUNE diseases , *RETROSPECTIVE studies , *INTERSTITIAL lung diseases , *KAPLAN-Meier estimator , *DESCRIPTIVE statistics , *SENSITIVITY & specificity (Statistics) , *CLUSTER analysis (Statistics) , *ALGORITHMS , *PROPORTIONAL hazards models , *PHENOTYPES , *SYMPTOMS , *DISEASE complications - Abstract
Objective To help identify homogeneous subgroups among patients with anti-PM-scleroderma-antibodies (PM-Scl-Abs) positive auto-immune diseases regardless of diagnostic classifications. Material and methods This multicentric (four hospitals) retrospective study collected all consecutive patients (from 2011 to 2021) with positive testing for anti-PM-Scl-Abs in a context of CTD. Subgroups of patients with similar clinico-biological phenotypes were defined using unsupervised multiple correspondence analysis and hierarchical clustering analysis of the features recorded in the first year of follow-up. Results One hundred and forty-two patients with anti-PM-Scl-Abs were evaluated and 129 patients were included in the clustering analysis and divided into three clusters. Cluster 1 (n = 47) included patients with frequent skin thickening, digestive involvement and interstitial lung disease (ILD) with non-specific interstitial pneumonia (NSIP). They were more likely to develop progressive fibrosing ILD. Cluster 2 (n = 36) included patients who all featured NSIP with frequent organizing pneumonia–associated pattern and mechanic's hands. This subgroup had increased risk of relapse and ILD was characterized by a good functional outcome. Cluster 3 (n = 46) was characterized by predominant or isolated musculoskeletal involvement and frequently matched UCTD criteria. Although very frequent among anti-PM-Scl-Abs positive patients, muscle involvement was less discriminating compared with skin thickening and ILD pattern to classify patients into subgroups. Conclusion Anti-PM-Scl-Abs associated auto-immune diseases are segregated into three subgroups with distinct clinical phenotype and outcomes. Skin thickening and NSIP are determinant predictors in segregation of theses populations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Occurrence of focal myositis during Behçet's disease: The identification of a specific vasculitis-associated focal myopathy.
- Author
-
Gallay, Laure, Hot, Arnaud, Allenbach, Yves, Maucort-Boulch, Delphine, Comarmond, Cloe, Marques, Cindy, Perard, Laurent, Simon, Anne, Mariampillai, Kuberaka, Cacoub, Patrice, Mery-Bossard, Laure, Cathebras, Pascal, Feasson, Leonard, Berezne, Alice, Morati, Chafika, Lessard, Lola, Faruch, Marie, Streichenberger, Nathalie, and Saadoun, David
- Subjects
BEHCET'S disease ,MYOSITIS ,DERMATOMYOSITIS ,MUSCLE diseases ,CREATINE kinase ,DISEASE relapse - Abstract
Aims: This study aimed to report the association of focal myositis (FM) and Behçet's disease (BD) and to analyse the main characteristics of such an association. Methods: This is a retrospective multicentre study of patients with BD and FM (BD + FM+ group) and those without FM (BD - FM+ group). Clinical, laboratory, radiological, pathological, treatment and outcome data were analysed. Results: The BD + FM+ group included 10 patients; the median [interquartile range] age at BD diagnosis was 25 [16-35] years, and at FM diagnosis, it was 30 [26-42] years. The diagnosis of BD preceded FM in the majority of cases (n = 8/10). FM occurrence was associated with BD flare-ups in three cases. The creatine kinase levels remained normal or slightly increased. Histological analyses identified relativelypreserved muscle tissue, associated with vasculitis (n = 5/6). All patients required treatment; most patients relapsed (n = 9/10). The BD - FM+ group included 35 patients. A comparison of the groups identified a trend towards a younger median age at diagnosis of FM among those with BD (p = 0.063) and more frequent focal muscle swelling in the BD + FM+ group (p = 0.029). The pathological analysis identified significantly less frequent muscle alterations in the BD + FM+ group (muscle fibre size heterogeneity, p = 0.021; necrosis, p = 0.007; and fibrosis, p = 0.027). BD + FM+ patients had a higher frequency of relapse (p = 0.003) and systematic treatment (p = 0.042). Conclusions: FM occurring during BD appears to be part of the systemic vasculitis process and presents as a vasculitis-associated focal myopathy with a specific clinicohistological pattern. Patients with this association require long-term follow-up and adapted management. This case series also highlights the need for research on BD diagnostic criteria in cases of FM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger
- Author
-
Toquet, Ségolène, Granger, Benjamin, Uzunhan, Yurdagul, Mariampillai, Kubéraka, Nunes, Hilario, Benveniste, Olivier, and Allenbach, Yves
- Published
- 2021
- Full Text
- View/download PDF
15. Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy
- Author
-
Monseau, Grégoire, Landon-Cardinal, Océane, Stenzel, Werner, Schoindre, Yoland, Mariampillai, Kubéraka, Barete, Stéphane, Martel, Clothilde, Masseau, Agathe, Meyer, Alain, Terrier, Benjamin, Guégan, Sarah, Verneuil, Laurence, Audia, Sylvain, Livideanu, Cristian Bulai, Hachulla, Eric, Kahn, Jean-Emmanuel, Lefevre, Guillaume, Maurier, François, Moulis, Guillaume, Papo, Thomas, Dossier, Antoine, Descamps, Vincent, Salort-Campana, Emmanuelle, Richard, Marie-Aleth, Bergot, Emmanuel, Mortier, Laurent, Costedoat-Chalumeau, Nathalie, Genot, Séverine, Perez, Florian, Piette, Anne-Marie, Samson, Maxime, Schleinitz, Nicolas, Zénone, Thierry, Lacoste, Marie, de Boysson, Hubert, Madaule, Serge, Rigolet, Aude, Champtiaux, Nicolas, Hervier, Baptiste, Bouvier, Anne-Marie, Jooste, Valérie, Léonard-Louis, Sarah, Maisonobe, Thierry, Aouba, Achille, Benveniste, Olivier, Bienvenu, Boris, and Allenbach, Yves
- Published
- 2020
- Full Text
- View/download PDF
16. Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients
- Author
-
Wesner, Nadège, Uruha, Akinori, Suzuki, Shigeaki, Mariampillai, Kubéraka, Granger, Benjamin, Champtiaux, Nicolas, Rigolet, Aude, Schoindre, Yoland, Lejeune, Sylvain, Guillaume-Jugnot, Perrine, Vautier, Matthieu, Hervier, Baptiste, Simon, Anne, Granier, Françoise, Gallay, Laure, Nishino, Ichizo, Benveniste, Olivier, and Allenbach, Yves
- Published
- 2020
- Full Text
- View/download PDF
17. Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis
- Author
-
Duchesne, Mathilde, primary, Leonard‐Louis, Sarah, additional, Landon‐Cardinal, Océane, additional, Anquetil, Céline, additional, Mariampillai, Kuberaka, additional, Monzani, Quentin, additional, Benveniste, Olivier, additional, and Allenbach, Yves, additional
- Published
- 2020
- Full Text
- View/download PDF
18. O33 Earlier cancer diagnosis after myositis onset is associated with improved long term survival: results from UK, French and Czech cohorts
- Author
-
Oldroyd, Alexander, primary, New, Paul, primary, Lamb, Janine, primary, Ollier, William, primary, Cooper, Robert, primary, Mariampillai, Kuberaka, primary, Benveniste, Olivier, primary, Vencovský, Jiří, primary, Mann, Heřman, primary, and Chinoy, Hector, primary
- Published
- 2020
- Full Text
- View/download PDF
19. Anti-RNP antibodies delineate a subgroup of necrotizing myositis
- Author
-
Wesner, Nadège, Uruha, Akinori, Suzuki, Shigeaki, Mariampillai, Kuberaka, Granger, Benjamin, Champtiaux, Nicolas, Rigolet, Aude, Schoindre, Yoland, Jeune, Sylvain Le, Guillaume-Jugnot, Perrine, Vautier, Mathieu, Hervier, Baptiste, Simon, Anne, Granier, Francoise, Gallay, Laure, Nishino, Ichizo, Benveniste, Olivier, Allenbach, Yves, Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Épidémiologie et Évaluation des Maladies Ostéoarticulaires Inflammatoires et Systémiques (GRC-08 EEMOIS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire de biologie et modélisation de la cellule (LBMC UMR 5239), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), and National Center of Neurology and Psychiatry [Tokyo, Japan]
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience
- Published
- 2019
- Full Text
- View/download PDF
20. Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study
- Author
-
Langlois, Vincent, primary, Gillibert, André, additional, Uzunhan, Yurdagül, additional, Chabi, Marie-Laure, additional, Hachulla, Eric, additional, Landon-Cardinal, Océane, additional, Mariampillai, Kuberaka, additional, Champtiaux, Nicolas, additional, Nunes, Hilario, additional, Benveniste, Olivier, additional, and Hervier, Baptiste, additional
- Published
- 2020
- Full Text
- View/download PDF
21. Ultrasensitive Interferons quantification in idiopathic inflammatory myopathies serve as biomarkers of activity in dermatomyositis and anti-synthetase syndrome
- Author
-
Loïs, BOLKO, primary, Anquetil, Celine, additional, llibre, Alba, additional, Maillard, Solene, additional, Amelin, Damien, additional, Dorgham, Karim, additional, Bondet, Vincent, additional, Landon-Cardinal, Oceane, additional, Toquet, Segolene, additional, Mariampillai, Kuberaka, additional, Mahoudeau, Alexandrine, additional, Hervier, Baptiste, additional, Rodero, Mathieu, additional, Gorochov, Guy, additional, Duffy, Darragh, additional, Benveniste, Olivier, additional, and Allenbach, Yves, additional
- Published
- 2020
- Full Text
- View/download PDF
22. Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
- Author
-
Allenbach, Yves, Yurdagul Uzunhan, Toquet, Segolene, Leroux, Gaelle, Gallay, Laure, Rigolet, Aude, Hervier, Baptiste, Champtiaux, Nicolas, Vautier, Mathieu, Guillaume, Perrine, Limal, Nicolas, Meyer, Alain, Deligny, Christophe, Bonnotte, Bernard, Devilliers, Herve, Audia, Sylvain, Samson, Maxime, Servettaz, Amelie, Costedoat, Nathalie, Saadoun, David, Diot, Elisabeth, Berezne, Alice, Mekinian, Arsene, Mariampillai, Kuberaka, Nunes, Hilario, Benveniste, Olivier, Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de médecine interne et maladies systémiques (SOC 2) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Bourgogne Franche-Comté [COMUE] (UBFC), FHU 'Integrated center for research in inflammatory diseases - InCREASe', Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département de Médecine Interne, Immunologie clinique et maladies infectieuses [CHU Reims], Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims), Immunologie - Immunopathologie - Immunothérapie [CHU Pitié Salpêtrière] (I3), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Médecine Interne et Maladies Infectieuses [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Service de Médecine Interne [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Centre de référence des maladies rares neuromusculaires, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and université de Bourgogne, LNC
- Subjects
[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Myositis ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Myopathy ,Interstitial lung disease ,ComputingMilieux_MISCELLANEOUS ,Dermatomyositis ,Autoantibodies - Abstract
International audience
- Published
- 2018
23. Moving from Dermatomyositis Associated with Anti-MelanomaDifferentiation-Associated Gene 5 Antibody to Anti-MelanomaDifferentiation-Associated Gene 5 Syndrome
- Author
-
Allenbach, Yves, Uzunhan, Yurdagul, Toquet, Ségolène, Leroux, Gaëlle, Gallay, Laure, Rigolet, Aude, Hervier, Baptiste, Champtiaux, Nicolas, Vautier, Mathieu, Guillaume, Perrine, Limal, Nicolas, Meyer, Alain, Deligny, Christophe, Bonnotte, Bernard, Devilliers, Hervé, Audia, Sylvain, Samson, Maxime, Servettaz, Amélie, Costedoat, Nathalie, Saadoun, David, Diot, Elisabeth, Berezne, Alice, Mékinian, Arsène, Mariampillai, Kuberaka, Nunes, Hilario, Benveniste, Olivier, Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hypoxie et Poumon : pneumopathologies fibrosantes, modulations ventilatoires et circulatoires (H&P), Université Paris 13 (UP13)-UFR SMBH, Institut de Myologie, Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de biologie et modélisation de la cellule (LBMC UMR 5239), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor [Créteil], Mitochondrie, stress oxydant et protection musculaire (MSP), Université de Strasbourg (UNISTRA), Service de Médecine interne [CHU de Fort-de France], CHU de Fort de France, Service de médecine interne et immunologie clinique (SOC 1) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de référence des maladies rares des cytopénies auto-immunes de l'adulte (CHU Dijon) (CRMR des cytopénies auto-immunes de l'adulte ), Département de Médecine Interne, Immunologie clinique et maladies infectieuses [CHU Reims], Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims), Immunologie - Immunopathologie - Immunothérapeutique (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Sorbonne Université (SU)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience
- Published
- 2018
- Full Text
- View/download PDF
24. Granulomatosis-associated myositis
- Author
-
Dieudonné, Yannick, primary, Allenbach, Yves, additional, Benveniste, Olivier, additional, Leonard-Louis, Sarah, additional, Hervier, Baptiste, additional, Mariampillai, Kuberaka, additional, Nespola, Benoit, additional, Lannes, Béatrice, additional, Echaniz-Laguna, Andoni, additional, Wendling, Daniel, additional, Von Frenckell, Christian, additional, Poursac, Nicolas, additional, Mortier, Emmanuel, additional, Lavigne, Christian, additional, Hinschberger, Olivier, additional, Magnant, Julie, additional, Gottenberg, Jacques-Eric, additional, Geny, Bernard, additional, Sibilia, Jean, additional, and Meyer, Alain, additional
- Published
- 2019
- Full Text
- View/download PDF
25. Necrosis in anti-SRP + and anti-HMGCR + myopathies
- Author
-
Allenbach, yves, Arouche-Delaperche, Louiza, Preusse, Corinna, Radbruch, Helena, Butler-Browne, Gillian, Champtiaux, Nicolas, Mariampillai, Kuberaka, Rigolet, Aude, Hufnagl, Peter, Zerbe, Norman, Amelin, Damien, Maisonobe, Thierry, Louis-Leonard, Sarah, Duyckaerts, Charles, Eymard, Bruno, Goebel, Hans-Hilmar, Bergua, Cecile, Drouot, Laurent, Boyer, Olivier, Benveniste, Olivier, Stenzel, Werner, Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Freie Universität Berlin, Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes, Thérapie des maladies du muscle strié, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU), Centre de référence des maladies rares neuromusculaires, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de médecine interne [CHU Pitié-Salpétrière], Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Association française contre les myopathies (AFM-Téléthon)-Sorbonne Université (SU), Service de Neurophysiologie [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Association française contre les myopathies (AFM-Téléthon)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Pierre et Marie Curie - Paris 6 (UPMC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de référence des maladies rares neuromusculaires [CHU Pitié-Salpétriêre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV]Life Sciences [q-bio] ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2018
- Full Text
- View/download PDF
26. Rapamycin vs. Placebo for the Treatment of Inclusion Body Myositis: improvement of the 6 min walking distance, a functional scale, the FVC and muscle quantitative MRI
- Author
-
Benveniste, Olivier, Hogrel, Jean-Yves, Annoussamy, Melanie, Bachasson, Damien, Rigolet, Aude, Servais, Laurent, Salem, Joe-Elie, Hervier, Baptiste, Cardinal, Oceane Landon, Mariampillai, Kuberaka, Hulot, Jean-Sebastien, Carlier, Pierre, Allenbach, Yves, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut de Myologie, Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut pour la Recherche sur la Moelle Epinière et l'Encéphale (IRME), Institute of Myology Paris France, Service of Clinical Trials and Databases, Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] (CIC Paris-Est), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP]
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience
- Published
- 2017
27. Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice
- Author
-
Landon-Cardinal, Océane, primary, Devilliers, Hervé, additional, Chavarot, Nathalie, additional, Mariampillai, Kuberaka, additional, Rigolet, Aude, additional, Hervier, Baptiste, additional, Allenbach, Yves, additional, and Benveniste, Olivier, additional
- Published
- 2019
- Full Text
- View/download PDF
28. Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies
- Author
-
Mauhin, Wladimir, primary, Mariampillai, Kuberaka, additional, Allenbach, Yves, additional, Charuel, Jean-Luc, additional, Musset, Lucile, additional, and Benveniste, Olivier, additional
- Published
- 2018
- Full Text
- View/download PDF
29. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients
- Author
-
Masat, Elisa, Laforêt, Pascal, De Antonio, Marie, Corre, Guillaume, Perniconi, Barbara, Taouagh, Nadjib, Mariampillai, Kuberaka, Amelin, Damien, Mauhin, Wladimir, Hogrel, Jean-Yves, Caillaud, Catherine, Ronzitti, Giuseppe, Puzzo, Francesco, Kuranda, Klaudia, Colella, Pasqualina, Mallone, Roberto, Benveniste, Olivier, Mingozzi, Federico, Bassez, G., Bedat-Millet, A. L., Behin, A., Eymard, B., Leonard-Louis, S., Stojkovic, T., Canal, A., Decostre, V., Bouhour, F., Boyer, F., Castaing, Y., Chapon, F., Cintas, P., Durieu, I., Echaniz-Laguna, A., Feasson, L., Furby, A., Hamroun, D., Ferrer, X., Solé, G., Froissart, R., Piraud, M., Germain, D., Benistan, K., Guffon-Fouilhoux, N., Journel, H., Labauge, P., Lacour, A., Levy, A., Magot, A., Péréon, Y., Minot-Myhié, M. -C., Nadaj-Pakleza, A., Nathier, C., Orlikowski, D., Pellegrini, N., Petiot, P., Praline, J., Lofaso, F., Prigent, H., Dutry, A., Renard, D., Sacconi, S., Desnuelle, C., Salort-Campana, E., Pouget, J., Tiffreau, V., Vincent, D., Zagnoli, F., Centre de recherche en myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche des Cordeliers (CRC), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Généthon, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de biochimie métabolique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de diabétologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Association française contre les myopathies ( AFM-Téléthon ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Association française contre les myopathies ( AFM-Téléthon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), GENETHON, Genethon, DHUI2B, CHU Pitié-Salpêtrière [APHP], CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Université Pierre et Marie Curie - Paris 6 [UPMC], CHU Necker - Enfants Malades [AP-HP], Hôpital Cochin [AP-HP], Hôpital Henri Mondor, CHU Rouen, Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Centre Hospitalier Universitaire de Reims [CHU Reims], CHU de Bordeaux Pellegrin [Bordeaux], CHU Caen, Centre d'investigation clinique de Toulouse [CIC 1436], Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E], CHU Montpellier, CHU Bordeaux [Bordeaux], Hôpital de l'Hôtel Dieu [CHU-HCL], Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille], Centre hospitalier universitaire de Nantes [CHU Nantes], CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire d'Angers [CHU Angers], Hôpital Raymond Poincaré [AP-HP], Hôpital de la Croix-Rousse [CHU - HCL], Centre Hospitalier Régional Universitaire de Tours [CHRU Tours], Centre Hospitalier Universitaire de Nice [CHU Nice], Hôpital de la Timone [CHU - APHM] [TIMONE], Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 [URePSSS], Hôpital d'Instruction des Armées Clermont Tonnerre, Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), and HAL UPMC, Gestionnaire
- Subjects
0301 basic medicine ,Adult ,Male ,Chemokine ,congenital, hereditary, and neonatal diseases and abnormalities ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,T cell ,T-Lymphocytes ,Antibodies ,Article ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Medicine ,[ SDV.IMM ] Life Sciences [q-bio]/Immunology ,Humans ,Enzyme Replacement Therapy ,Age of Onset ,Aged ,[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Multidisciplinary ,biology ,business.industry ,Glycogen Storage Disease Type II ,Immunogenicity ,Case-control study ,Antibody titer ,nutritional and metabolic diseases ,alpha-Glucosidases ,Enzyme replacement therapy ,Dendritic Cells ,[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Middle Aged ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,3. Good health ,030104 developmental biology ,medicine.anatomical_structure ,Treatment Outcome ,Case-Control Studies ,Immunoglobulin G ,Immunology ,biology.protein ,Interleukin-2 ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,Antibody ,business ,030217 neurology & neurosurgery - Abstract
Immunogenicity of recombinant human acid-alpha glucosidase (rhGAA) in enzyme replacement therapy (ERT) is a safety and efficacy concern in the management of late-onset Pompe disease (LOPD). However, long-term effects of ERT on humoral and cellular responses to rhGAA are still poorly understood. To better understand the impact of immunogenicity of rhGAA on the efficacy of ERT, clinical data and blood samples from LOPD patients undergoing ERT for >4 years (n = 28) or untreated (n = 10) were collected and analyzed. In treated LOPD patients, anti-rhGAA antibodies peaked within the first 1000 days of ERT, while long-term exposure to rhGAA resulted in clearance of antibodies with residual production of non-neutralizing IgG. Analysis of T cell responses to rhGAA showed detectable T cell reactivity only after in vitro restimulation. Upregulation of several cytokines and chemokines was detectable in both treated and untreated LOPD subjects, while IL2 secretion was detectable only in subjects who received ERT. These results indicate that long-term ERT in LOPD patients results in a decrease in antibody titers and residual production of non-inhibitory IgGs. Immune responses to GAA following long-term ERT do not seem to affect efficacy of ERT and are consistent with an immunomodulatory effect possibly mediated by regulatory T cells.
- Published
- 2016
- Full Text
- View/download PDF
30. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
- Author
-
Allenbach, Yves, primary, Keraen, Jeremy, additional, Bouvier, Anne-marie, additional, Jooste, Valérie, additional, Champtiaux, Nicolas, additional, Hervier, Baptiste, additional, Schoindre, Yoland, additional, Rigolet, Aude, additional, Gilardin, Laurent, additional, Musset, Lucile, additional, Charuel, Jean-Luc, additional, Boyer, Olivier, additional, Jouen, Fabienne, additional, Drouot, Laurent, additional, Martinet, Jeremie, additional, Stojkovic, Tanya, additional, Eymard, Bruno, additional, Laforêt, Pascal, additional, Behin, Antony, additional, Salort-Campana, Emmanuelle, additional, Fain, Olivier, additional, Meyer, Alain, additional, Schleinitz, Nicolas, additional, Mariampillai, Kuberaka, additional, Grados, Aurelie, additional, and Benveniste, Olivier, additional
- Published
- 2016
- Full Text
- View/download PDF
31. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial
- Author
-
Allenbach, Yves, primary, Guiguet, Marguerite, additional, Rigolet, Aude, additional, Marie, Isabelle, additional, Hachulla, Eric, additional, Drouot, Laurent, additional, Jouen, Fabienne, additional, Jacquot, Serge, additional, Mariampillai, Kuberaka, additional, Musset, Lucile, additional, Grenier, Philippe, additional, Devilliers, Herve, additional, Hij, Adrian, additional, Boyer, Olivier, additional, Herson, Serge, additional, and Benveniste, Olivier, additional
- Published
- 2015
- Full Text
- View/download PDF
32. Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement.
- Author
-
Allenbach, Yves, Arouche-Delaperche, Louiza, Preusse, Corinna, Radbruch, Helena, Butler-Browne, Gillian, Champtiaux, Nicolas, Mariampillai, Kuberaka, Rigolet, Aude, Hufnagl, Peter, Zerbe, Norman, Amelin, Damien, Maisonobe, Thierry, Louis-Leonard, Sarah, Duyckaerts, Charles, Eymard, Bruno, Goebel, Hans-Hilmar, Bergua, Cecile, Drouot, Laurent, Boyer, Olivier, and Benveniste, Olivier
- Published
- 2018
- Full Text
- View/download PDF
33. Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis.
- Author
-
Bolko L, Anquetil C, Llibre A, Maillard S, Amelin D, Dorgham K, Bondet V, Landon-Cardinal O, Toquet S, Mariampillai K, Malatre S, Mahoudeau A, Hervier B, Rodero M, Gorochov G, Duffy D, Benveniste O, and Allenbach Y
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Cytokines blood, Interferons blood, Severity of Illness Index, Dermatomyositis blood, Dermatomyositis immunology, Dermatomyositis diagnosis, Biomarkers blood, Myositis blood, Myositis immunology, Myositis diagnosis
- Abstract
Objective: The objective of this study was to evaluate the presence of different types of interferon in idiopathic inflammatory myopathies (IIM) and their subgroups using ultrasensitive cytokine detection techniques (SIMOA) and to assess their potential as activity biomarkers., Methods: Disease activity was measured at the time of serum collection and assessed by manual muscle testing eight (MMT8 score 0-150), muscle enzymes to calculate the Physician Global Assessment (PGA) (0-10). Patients were classified as active if PGA>5.Serum IFN-α and IFN-γ levels was measured using the single molecule array (SIMOA) technique. Serum IFN-β level was measured by Elisa. Correlation between IFN levels and disease activity were performed., Results: We included 242 IIM patients and found a good correlation between type I Interferon (IFN) and dermatomyositis disease activity. IFN-α and IFN-β was highly correlated with disease activity (r=0.76 and r=0,58). To evaluate whether the different types of Interferons could serve as biomarkers of activity, we generated ROC curves. Patients with active DM had a higher median IFN-α level (0.49 pg/ml [0.1-3.7]) compared with non-active patients (0.03 pg/ml [0.01-0.07] p<0.05). The area under the curve was 0.90 IC95 (0.76-0.97) p<0.05. Furthermore, Myositis-specific antibodies appear to be associated with a different secretion profile; patients with anti-MDA 5 antibodies had higher level of IFN-α than most other antibodies (6.58 vs 0.14 p<0.005). NXP2 had higher IFN-β level than patients with Tif1γ antibodies., Conclusion: Serum IFN-α level measured by SIMOA is a reliable biomarker of DM activity. Myositis-specific antibodies appear to be associated with a different secretion profile. This data needs to be confirmed in order to select the good therapeutics strategies in DM., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2025 Bolko, Anquetil, Llibre, Maillard, Amelin, Dorgham, Bondet, Landon-Cardinal, Toquet, Mariampillai, Malatre, Mahoudeau, Hervier, Rodero, Gorochov, Duffy, Benveniste and Allenbach.)
- Published
- 2025
- Full Text
- View/download PDF
34. Necrosis in anti-SRP + and anti-HMGCR + myopathies: Role of autoantibodies and complement.
- Author
-
Allenbach Y, Arouche-Delaperche L, Preusse C, Radbruch H, Butler-Browne G, Champtiaux N, Mariampillai K, Rigolet A, Hufnagl P, Zerbe N, Amelin D, Maisonobe T, Louis-Leonard S, Duyckaerts C, Eymard B, Goebel HH, Bergua C, Drouot L, Boyer O, Benveniste O, and Stenzel W
- Subjects
- Antigens, CD metabolism, Endoplasmic Reticulum metabolism, Female, Humans, Hydroxymethylglutaryl CoA Reductases metabolism, Interleukin-1beta genetics, Interleukin-1beta metabolism, Lymphocytes pathology, Macrophages pathology, Male, Muscle, Skeletal metabolism, Muscle, Skeletal ultrastructure, Myofibrils metabolism, Myofibrils pathology, Necrosis etiology, Neural Cell Adhesion Molecules metabolism, Nitric Oxide Synthase Type II genetics, Nitric Oxide Synthase Type II metabolism, RNA, Messenger metabolism, Signal Recognition Particle metabolism, Autoantibodies blood, Complement System Proteins metabolism, Hydroxymethylglutaryl CoA Reductases immunology, Muscle, Skeletal pathology, Muscular Diseases blood, Muscular Diseases complications, Signal Recognition Particle immunology
- Abstract
Objective: To characterize muscle fiber necrosis in immune-mediated necrotizing myopathies (IMNM) with anti-signal recognition particle (SRP) or anti-3-hydroxy-3-methylglutarylcoenzyme A reductase (HMGCR) antibodies and to explore its underlying molecular immune mechanisms., Methods: Muscle biopsies from patients with IMNM were analyzed and compared to biopsies from control patients with myositis. In addition to immunostaining and reverse transcription PCR on muscle samples, in vitro immunostaining on primary muscle cells was performed., Results: Creatine kinase levels and muscle regeneration correlated with the proportion of necrotic fibers ( r = 0.6, p < 0.001). CD68
+ iNOS+ macrophages and a Th-1 immune environment were chiefly involved in ongoing myophagocytosis of necrotic fibers. T-cell densities correlated with necrosis but no signs of cytotoxicity were detected. Activation of the classical pathway of the complement cascade, accompanied by deposition of sarcolemmal immunoglobulins, featured involvement of humoral immunity. Presence of SRP and HMGCR proteins on altered myofibers was reproduced on myotubes exposed to purified patient-derived autoantibodies. Finally, a correlation between sarcolemmal complement deposits and fiber necrosis was observed ( r = 0.4 and p = 0.004). Based on these observations, we propose to update the pathologic criteria of IMNM., Conclusion: These data further corroborate the pathogenic role of anti-SRP and anti-HMGCR autoantibodies in IMNM, highlighting humoral mechanisms as key players in immunity and myofiber necrosis., (© 2018 American Academy of Neurology.)- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.